Mauna Kea (ENT:MKEA) today touted the results from a recently published study of its Cellvizio system which supported the use of the device in diagnosing pancreatic cysts.
The Cellvizio device is designed for use in a variety of surgical procedures, providing real time visualization at the microscopic level, Mauna Kea said.
Results from the study were published in the World Journal of Gastroenterology, the French company said.
In the study, researchers evaluated in vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions, Mauna Kea reported. The researchers concluded that in vivo nCLE patterns were reproducible in ex vivo pCLE for all major neoplastic pancreatic cysts.
“This new peer reviewed study led by Dr. Krishna provides further validation of the application of Cellvizio needle-based CLE in the diagnosis of pancreatic cysts. There is a significant opportunity for clinicians to use optical biopsy with Cellvizio in the often-challenging task of diagnosing pancreatic cysts, allowing them to make faster diagnoses and better treatment decisions to achieve better outcomes for their patients,” CEO Sacha Loiseau said in a prepared release.
In May, Mauna Kea touted data from a study examining the use of its Cellvizio platform in assessing acute lung rejection following transplant.
Results from follow-up exams of 24 lung transplant patients were used in the study, with CLE video-imaging obtained prior to tissue sampling, Mauna Kea said. Endomicroscopy video-images from the Cellvizio were blindly reviewed by 4 pulmonologists independently and then with a consensus meeting.
